CTORescues

First Phosphate Announces Intention to Complete $2,000,000 Non-Brokered Private Placement to Strategic Investor. The gross proceeds from the Flow-Through Offering are to be used to incur "Canadian exploration expenses"...

First Phosphate Announces $2 Million Private Placement Offering - StockNews24 First Phosphate Announces Intention to Complete $2,000,000 Non-Brokered Private Placement to Strategic Investor. The gross proceeds from the Flow-Through Offering are to be used to incur "Canadian exploration expenses"

BioVaxys Technology Corp. is developing its patented DPX™ platform to address the challenges of lipid nanoparticles (LNPs) in mRNA vaccine delivery. Learn how DPX improves stability, immune responses, and manufacturing economics as the mRNA vaccine market projects $48 billion growth by 2030....

BioVaxys Advances DPX™ as mRNA Vaccine Carrier Amid USD $48B Market Growth BioVaxys Technology Corp. is developing its patented DPX™ platform to address the challenges of lipid nanoparticles (LNPs) in mRNA vaccine delivery. Learn how DPX improves stability, immune responses, and manufacturing economics as the mRNA vaccine market projects $48 billion growth by 2030.